COSCIENS Biopharma Inc.

OTCPK:CSCI.D Stock Report

Market Cap: US$5.7m

COSCIENS Biopharma Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for COSCIENS Biopharma.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth24.7%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Seeking Alpha • Aug 29

Aeterna Zentaris to regain full rights to Macrilen oral test from Novo Nordisk

Aeterna Zentaris (NASDAQ:AEZS) on Monday said it would regain the U.S. and Canadian rights for Macrilen, an oral test to detect adult growth hormone deficiency, from Danish pharmaceutical company Novo Nordisk (NVO). The company said it would get the rights back after NVO decided to terminate the amended development and commercialization licensing agreement between the two parties. NVO will have a 270-day notice period in which it will continue to sell and promote Macrilen in the U.S. "In light of Novo Nordisk’s decision, Aeterna plans to engage in robust business development efforts to identify and secure a new development and commercialization partner," AEZS said in a statement. AEZS stock -1.8% to $5 in morning trading.
Seeking Alpha • Jul 19

Aeterna slips ~10% after announcing date of reverse stock split

The shares of the commercial-stage biotech Aeterna Zentaris (NASDAQ:AEZS) dropped ~10% in the morning hours Tuesday after the company disclosed that its previously announced 1-25 reverse stock split would take effect this week. Accordingly, the common shares of Aeterna (AEZS) will start trading on a split-adjusted basis on or about the opening of trading on July 21. The consolidation is expected to reduce the issued and outstanding common shares to ~4.9M from ~121.4M, Aeterna (AEZS) said. The reverse stock split is aimed at meeting the Nasdaq’s minimum bid price requirement to keep the minimum bid price above US$1.00 for a minimum of at least ten consecutive days. However, the company is unlikely to satisfy the listing rule before July 25, the current expiration date of its grace period. A potential notice of delisting during that week will give seven calendar days for Aeterna (AEZS) to request a hearing. The company expects to regain compliance by August 03 following the reverse stock split. In mid-July, Aeterna (AEZS) obtained shareholder approval for the proposed share consolidation.

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as COSCIENS Biopharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

OTCPK:CSCI.D - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/20268-8-9-9N/A
12/31/20257-10-9-8N/A
9/30/20259-14-11-10N/A
6/30/20259-18-18-17N/A
3/31/20259-17-15-14N/A
12/31/202410-15-16-15N/A
9/30/20249-7-11-9N/A
6/30/20248-5-6-5N/A
3/31/20247-5-5-4N/A
12/31/20237-3-3-3N/A
9/30/20236-18-8-8N/A
6/30/20238-17-9-9N/A
3/31/20237-20-13-13N/A
12/31/202215355N/A
9/30/20224-13-13-13N/A
6/30/20223-12-10-10N/A
3/31/20225-10-9-9N/A
12/31/20215-8-9-9N/A
9/30/20217-7-4-4N/A
6/30/20216-6-4-4N/A
3/31/20214-7-3-3N/A
12/31/20204-5-4-4N/A
9/30/20201-5-10-10N/A
6/30/20201-4-10-10N/A
3/31/202020-10-10N/A
12/31/20191-6N/A-11N/A
9/30/20192-10N/A-10N/A
6/30/20192-12N/A-10N/A
3/31/20192-15N/A-13N/A
12/31/2018274N/A7N/A
9/30/2018269N/A5N/A
6/30/2018252N/A2N/A
3/31/2018252N/A1N/A
12/31/20171-17N/A-23N/A
9/30/20171-25N/A-27N/A
6/30/20171-21N/A-27N/A
3/31/20171-25N/A-27N/A
12/31/20161-25N/A-29N/A
9/30/20161-27N/A-29N/A
6/30/20161-36N/A-31N/A
3/31/20161-44N/A-33N/A
12/31/20151-50N/A-34N/A
9/30/20150-36N/A-34N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if CSCI.D's forecast earnings growth is above the savings rate (3.5%).

Earnings vs Market: Insufficient data to determine if CSCI.D's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if CSCI.D's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if CSCI.D's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if CSCI.D's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CSCI.D's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/23 23:27
End of Day Share Price 2026/07/23 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

COSCIENS Biopharma Inc. is covered by 11 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Douglas LoeCantor Fitzgerald Canada Corporation
Charles DuncanCitizens JMP Securities, LLC
Pooya HemamiDesjardins Securities Inc.